Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13101426 | 0.83 | LMNA (0.57) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL3353769 | 0.78 | LMNA (0.60) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL2606746 | 0.78 | — | — | |
| SCHEMBL7592324 | 0.75 | — | — | |
| SCHEMBL11745129 | 0.70 | — | — | |
| SCHEMBL20988101 | 0.67 | LMNA (0.48) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL23606873 | 0.67 | — | — | |
| SCHEMBL7951950 | 0.67 | — | — | |
| SCHEMBL15630450 | 0.67 | — | — | |
| SCHEMBL5775460 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653306-B1 | Process for production of serinol and its bis-adduct | Penn A Kem LLC (US) | 2014-02-18 | — | — | US | claimed |
| EP-1159255-A2 | BIS(1,3-DIHYDROXY-PROP-2-YL)AMINE AND DERIVATIVES THEREOF IN THE MANUFACTURE OF POLYMERS | ISIS INNOVATION LIMITED (GB) | 2001-12-05 | — | — | EP | claimed |
| WO-2000055111-A2 | BIS(1,3-DIHYDROXY-PROP-2-YL)AMINE AND DERIVATIVES THEREOF IN THE MANUFACTURE OF POLYMERS | ISIS INNOVATION LIMITED (GB) | 2000-09-21 | — | — | WO | claimed |
| US-20260125344-A1 | POLYURETHANE-ACETOACETATE COMPOUNDS | PPG INDUSTRIES OHIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4423059-A2 | POLYURETHANE-ACETOACETATE COMPOUNDS | PPG Industries Ohio, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076835-A2 | POLYURETHANE-ACETOACETATE COMPOUNDS | PPG INDUSTRIES OHIO, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-8653306-B1 | Process for production of serinol and its bis-adduct | Penn A Kem LLC (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653306-B1 | Process for production of serinol and its bis-adduct | Penn A Kem LLC (US) | 2014-02-18 | — | — | US | disclosed |
| US-6916948-B2 | Bis(1,3-dihydroxy-prop-2-yl) amine and derivatives thereof in the manufacture of polymers | ISIS INNOVATION LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-6916948-B2 | Bis(1,3-dihydroxy-prop-2-yl) amine and derivatives thereof in the manufacture of polymers | ISIS INNOVATION LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-6916948-B2 | Bis(1,3-dihydroxy-prop-2-yl) amine and derivatives thereof in the manufacture of polymers | ISIS INNOVATION LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| EP-0839032-A4 | HYDROXYL IONS AS UNIQUE THERAPEUTIC AGENTS AND COMPOUNDS THAT MODULATE IONS, COMPOUNDS | FHJ SCIENT INC (US) | 1998-07-08 | — | — | EP | disclosed |
| EP-0839032-A1 | HYDROXYL IONS AS UNIQUE THERAPEUTIC AGENTS AND COMPOUNDS THAT MODULATE IONS, COMPOUNDS | FHJ SCIENTIFIC, INC. (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5679711-A | Hydroxyl ions as novel therapeutic agents and compounds that modulate these ions, compositions employing these agents, therapeutic methods for using such agents | FHJ SCIENTIFIC, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| WO-1996040104-A1 | HYDROXYL IONS AS UNIQUE THERAPEUTIC AGENTS AND COMPOUNDS THAT MODULATE IONS, COMPOUNDS | FHJ SCIENTIFIC, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5585391-A | Hydroxyl ions as unique therapeutic agents and compounds that modulate these ions, compositions employing these agents, therapeutic methods for using such agents and processes for preparing them | FHJ SCIENTIFIC, INC. (US) | 1996-12-17 | — | — | US | disclosed |
| US-5574050-A | Hydroxyl ions as unique therapeutic agents and processes for preparing them | FHJ SCIENTIFIC, INC. (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0725636-A1 | HYDROXYL IONS AS UNIQUE THERAPEUTIC AGENTS AND COMPOUNDS THAT MODULATE THESE IONS, COMPOSITIONS EMPLOYING THESE AGENTS, THERAPEUTIC METHODS FOR USING SUCH AGENTS AND PROCESSES FOR PREPARING THEM | FHJ SCIENTIFIC, INC. (US) | 1996-08-14 | — | — | EP | disclosed |
| US-5514808-A | Hydroxyl ions as unique therapeutic agents and compounds that modulate these ions | FHJ SCIENTIFIC, INC (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1995010272-A1 | HYDROXYL IONS AS UNIQUE THERAPEUTIC AGENTS AND COMPOUNDS THAT MODULATE THESE IONS, COMPOSITIONS EMPLOYING THESE AGENTS, THERAPEUTIC METHODS FOR USING SUCH AGENTS AND PROCESSES FOR PREPARING THEM | FHJ SCIENTIFIC, INC. (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125344-A1 | POLYURETHANE-ACETOACETATE COMPOUNDS | HAT1, PUF60, GAR1 | LMNA 1125/4885TDP1 953/4885CNR1 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.